Close this search box.

ICER Misses the Numbers That Matter

The Institute for Clinical and Economic Review wants to assess the cost-effectiveness of breakthrough drugs for cystic fibrosis. But their analysis overlooks key points. View the Graphic

Comments on ICER’s Draft Evidence Report: Modulator Treatments for Cystic Fibrosis

Cystic fibrosis is a devastating disease that severely restricts patients’ quality of life and is associated with a shorter lifespan. The economic costs for managing cystic fibrosis are high. According to the American Thoracic Society, the average cost of care for cystic fibrosis was $48,000 in 2006. A good deal of these costs are costs […]

Comments on ICER’s Draft Evidence Report: Acute Treatment for Migraine

Migraine is a disabling condition for far too many Americans. Effective migraine control can meaningfully improve the quality of life for patients living with this disease, and can also provide offsetting health care savings. It is imperative that the any cost-effectiveness evaluation accounts for the full benefits enabled by medicines that offer effective migraine control. […]

Comments on Draft Scoping Document for Modular Cystic Fibrosis Treatment

Not only is cystic fibrosis a devastating disease, most patients living with cystic fibrosis do not have access to an effective treatment. The results from clinical studies indicate that the addition of the new triple therapy will make treatment possible for around 90 percent of patients. The patient community is eager for this advance, and […]

Comments on ICER’s Type 2 Diabetes Report

Several methodological issues in the draft evidence report for oral semaglutide are likely biasing the results toward an overly restrictive cost-effectiveness result. These issues include: Not adequately accounting for the additional patient benefits that a once-daily oral formulation provides Not adequately accounting for the co-morbidities associated with Type 2 diabetes Underestimating the full costs Type […]